Research Impact: Histotripsy

Author | Jina Sawani

Patient receiving histotripsy treatment with health care providers using equipment
Photo credit: Mandi Wright/Detroit Free Press

In late 2023, the United States Food and Drug Administration (FDA) approved the use of sound waves to break down tumors — a technique called histotripsy — in humans for liver treatment. 

This new therapy, which was developed at the University of Michigan and received support from the National Institutes of Health, provides a non-invasive alternative to surgery, chemotherapy and radiation treatments for cancer, which often have significant and life-altering side effects.

A clinical trial underway since 2021 at the U-M Rogel Cancer Center and other locations has treated patients with primary and metastatic liver tumors via histotripsy. This trial demonstrated the technology’s ability to meet the testing’s primary effectiveness and safety targets.

Dr. Mishal Mendiratta-Lala, professor of radiology with Michigan Medicine and principal investigator on the trial at U-M, worked with Dr. Zhen Xu, U-M professor of biomedical engineering and an inventor of the histotripsy approach, Dr. Clifford Cho, chief medical officer of UM Health-West, Dr. Neehar Parikh, Michigan Medicine transplant hepatologist, and a close knit team of fellow experts to develop, refine and  safely implement the new technology that works by using targeted and high intensity ultrasound waves to form microbubbles within liver tumors. The forces created as those bubbles form and collapse cause the tumor masses to break apart, killing their cells and leaving the debris to be cleaned up by the immune system.

Histotripsy technology ultimately means patients can receive non-invasive cancer treatment with fewer side effects, shorter recovery times, and less treatment discomfort. And in an exciting development, Dr. Cho is now working closely with colleagues in the Cancer Network of West Michigan (a partnership between UM Health-West and Trinity Health) to establish a new histotripsy program that will provide patients in west Michigan with easier access to this groundbreaking technology.

The Detroit Free Press ran a front-page story featuring Drs. Mendiratta-Lala and Xu, and their pioneering work related to histotripsy. The piece highlights the story of Elissa Robinson, a patient from Macomb Township, Mich., who was among the first five people in Michigan to undergo histotripsy to treat liver tumors.


More Articles About:

Research Impact Histotripsy

In This Story

clifford_suhyun_cho_md

Clifford S Cho

Professor

Mishal Mendiratta-Lala

Mishal Mendiratta-Lala, MD

Clinical Professor

parikh-neehar

Neehar Dilip Parikh MD, MS

Associate Professor

University of Michigan block M logo

Zhen Xu

Professor

Related

machine beige black
Health Lab

Histotripsy liver tumor trial successful, early clinical adoption recommended

The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert explains more about it in this article.

Featured News & Stories

Michael Powers pictured here holding a fish he caught as he stands in a boat. He struggled with pancreatitis for several decades and found answers at University of Michigan Health.
Health Lab

Patient with rare form of diabetes finds answers in genetic testing, clinical trials

Discover how genetic testing and a groundbreaking clinical trial helped one man overcome rare hyperchylomicronemia, high triglycerides, and pancreatitis.
Woman's torso in a blue hospital gown, with her hands holding a pregnant belly and an IV in place.
Health Lab

High dose oxytocin protocol linked to lower postpartum hemorrhage rates

A change in how oxytocin is administered after childbirth may help reduce postpartum hemorrhage, a new study suggests.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Zhen Xu, the Li Ka Shing Professor of Biomedical Engineering, a professor of radiology and neurosurgery, and a co-inventor of histotripsy, speaks at the ribbon cutting for the U-M Histotripsy Center.
News Release

Histotripsy research center launches to advance sound-wave-based cancer treatment

Expanding use of a non-invasive, ultrasound-based cancer treatment is the ultimate goal of the new University of Michigan Histotripsy Center, a first-of-its-kind facility launched Sept. 10.
woman taking her blood pressure on bed while pregnant
Health Lab

Researchers discover what may be the root cause of preeclampsia, and how to fix it

After years of research, a large team of multidisciplinary scientists from Michigan Medicine has identified a key molecular driver of preeclampsia, and demonstrated a potential way to counteract it in both mouse models and human placental tissue.
Zhen Xu, Ph.D.
News Release

Xu named among Time magazine’s most influential in health

U-M Health Rogel Cancer Center research member Zhen Xu, Ph.D., was selected to Time magazine’s TIME100 Health.